SlideShare a Scribd company logo
BY
Dr. SAMINATHAN KAYAROHANAM
M.PHARM, PhD, M.B.A, PhD
ANTIDIABETIC DRUGS
1
2
S.NO TITLE PAGE
1 OVERVIEW OF DIABETES MELLITUS 4-8
2 PATHOPHYSIOLOGY DIABETES MELLITUS 9
3 TYPES OF DIABETES 10
4 WHO DIABETES DIAGNOSTIC CRITERIA 18
5 MOST SIGNIFICANT SYMPTOMS OF DIABETES 19,20
6 CLASSIFICATION AND MECHANISM OF ANTIDIABETIC
DRUG
21,22
7 CLASSIFICATION AND MECHANISAM OF INSULLIN 23-25
8 DURATION OF ACTION OF SOME ORAL HYPOGLYCEMIC
AGENTS
26
9 SOME ADVERSE EFFECTS OBSERVED WITH ORAL
HYPOGLYCEMIC AGENTS
27
10 ADVERSE EFFECTS OBSERVED WITH INSULIN 28
TABLE OF CONTENT
Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
3Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
LEARNING OUTCOMES
1. Able to understand the diabetes mellitus
2. Able to demonstrate the diagnosis and symptom of diabetes
mellitus
3. Able to classified the different types of diabetes mellitus
4. Able to list the classification of drug used to treat diabetes
mellitus
5. Able to demonstrate the various mechanism of anti-diabetes
drugs
6. Able to understand some side effects of anti-diabetes drugs
4Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
 Diabetes mellitus is derived from the Greek word diabetes meaningsiphon -
to pass through and the Latin word mellitus meaning honeyed or sweet.
This is because in diabetes excess sugar is found in blood as well as the
urine.
 Diabetes mellitus (DM), commonly referred to as diabetes, is a group of
metabolic diseases in which there are high blood sugar levels over a
prolonged period. Symptoms of high blood sugar (hyperglycaemia) include
frequent urination, increased thirst, and increased hunger.
 Diabetes is a chronic disease, which occurs when the pancreas does not
produce enough insulin, or when the body cannot effectively use the insulin
it produces. This leads to an increased concentration of glucose in the blood
 Type 1 diabetes (previously known as insulin-dependent or childhood-onset
diabetes) is characterized by a lack of insulin production.
 Type 2 diabetes (formerly called non-insulin-dependent or adult-onset
diabetes) is caused by the body’s ineffective use of insulin. It often results
from excess body weight and physical inactivity.
 Gestational diabetes is hyperglycaemia that is first recognized during
pregnancy.
1. OVERVIEW OF DIABETES MELLITUS
5Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
1. About 347 million people worldwide have diabetes
There is an emerging global epidemic of diabetes that can be traced back to
rapid increases in overweight, including obesity and physical inactivity.
2. Diabetes is predicted to become the 7th leading cause of death in the
world by the year 2030.Total deaths from diabetes are projected to rise by
more than 50% in the next 10 years.
3. There are two major forms of diabetes
Type 1 diabetes is characterized by a lack of insulin production and type 2
diabetes results from the body's ineffective use of insulin.
4. A third type of diabetes is gestational diabetes
This type is characterized by hyperglycaemia, or raised blood sugar, with values
above normal but below those diagnostic of diabetes, occurring during
pregnancy. Women with gestational diabetes are at an increased risk of
complications during pregnancy and at delivery. They are also at increased risk
of type 2 diabetes in the future.
5. Type 2 diabetes is much more common than type 1 diabetes
Type 2 accounts for around 90% of all diabetes worldwide. Reports of type 2
diabetes in children – previously rare – have increased worldwide. In some
countries, it accounts for almost half of newly diagnosed cases in children and
adolescents.
WHO 10 FACTS OF DIABETES MELLITUS
6Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
6. Cardiovascular disease is responsible for between 50% and 80% of
deaths in people with diabetes
Diabetes has become one of the major causes of premature illness and death
in most countries, mainly through the increased risk of cardiovascular disease
(CVD).
7. In 2012 diabetes was the direct cause of 1.5 million deaths.
8. 80% of diabetes deaths occur in low- and middle-income countries
In developed countries most people with diabetes are above the age of
retirement, whereas in developing countries those most frequently affected are
aged between 35 and 64.
9. Diabetes is a leading cause of blindness, amputation and kidney failure
Lack of awareness about diabetes, combined with insufficient access to health
services and essential medicines, can lead to complications such as blindness,
amputation and kidney failure.
10. Type 2 diabetes can be prevented
Thirty minutes of moderate-intensity physical activity on most days and a
healthy diet can drastically reduce the risk of developing type 2 diabetes. Type
1 diabetes cannot be prevented.
Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D 7
8Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
INTERNATIONAL DIABETES FEDERATION
ESTIMATION IN 2015
9Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
2. PATHOPHYSIOLOGY DIABETES MELLITUS
10Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
3. TYPES OF DIABETES
TYPE I
(FORMALLY IDDM OR
JUVENILE)
TYPE II
(FORMALLY NIDDM
OR ADULT)
SECONDARY DIABETES
(OCCUR ONLY IF THERE IS AN
UNDERLYING DISEASE) E,G,:
CUSHING DISEASE,
PANCREATECTOMY, GROWTH
HORMONE TUMOR.
GESTATIONAL
DIABETES
11Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
TYPE 1 DIABETES
A chronic condition in which the pancreas produces little or no insulin.
12Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
TYPE 2 DIABETES
A chronic condition that affects the way the body processes blood sugar (glucose).
13Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
A form of high blood sugar affecting pregnant women.
GESTATIONAL DIABETES
14Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
DIFFERENT BETWEEN TYPE1 AND 2
15Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
DIFFERENT BETWEEN TYPE1 AND 2
16Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
DIFFERENT BETWEEN TYPE1 AND 2
17Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
COMPARISON OF TYPE 1 AND 2 DIABETES
18Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
4. WHO DIABETES DIAGNOSTIC CRITERIA
•Fasting plasma glucose level ≥ 7.0 mmol/l (126 mg/dl)
•Plasma glucose ≥ 11.1 mmol/l (200 mg/dl) two hours after a 75 g oral glucose
load as in a glucose tolerance test
•Symptoms of high blood sugar and casual plasma glucose ≥ 11.1 mmol/l
(200 mg/dl)
•Glycated hemoglobin (HbA1C) ≥ 48 mmol/mol (≥ 6.5 DCCT %)
Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D 19
5. MOST SIGNIFICANT SYMPTOMS OF DIABETES
20Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
MOST SIGNIFICANT SYMPTOMS OF DIABETES
21Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
6.CLASSIFICATION AND MECHANISM OF ANTIDIABETIC DRUG
1
3
2
22Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
SUMMARY OF ORAL AGENTS USED TO TREAT DIABETES
4
7
6
5
23Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
7.CLASSIFICATION AND MECHANISAM OF INSULLIN
Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D 24
7. MECHANISAM OF INSULLIN
25Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
INJECTION LOCATION OF INSULLIN
26Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
8. DURATION OF ACTION OF SOME ORAL
HYPOGLYCEMIC AGENTS
27Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
9. SOME ADVERSE EFFECTS OBSERVED WITH ORAL
HYPOGLYCEMIC AGENTS
28Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
10. ADVERSE EFFECTS OBSERVED WITH INSULIN
29Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D

More Related Content

What's hot

Ryzodeg presentation in ramadan by dr shahjada selim
Ryzodeg presentation in ramadan by dr shahjada selimRyzodeg presentation in ramadan by dr shahjada selim
Ryzodeg presentation in ramadan by dr shahjada selim
Bangabandhu Sheikh Mujib Medical University
 
Treatment of diabetes mellitus
Treatment of diabetes mellitusTreatment of diabetes mellitus
Treatment of diabetes mellitus
Salman Sherwani
 
Pharmacotherapy of glaucoma
Pharmacotherapy of glaucomaPharmacotherapy of glaucoma
Pharmacotherapy of glaucoma
Dr.Arka Mondal
 
COPD new drugs new devices
COPD new drugs new devicesCOPD new drugs new devices
COPD new drugs new devices
Ashraf ElAdawy
 
sodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptx
sodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptxsodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptx
sodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptx
LawanYarimaMasaba
 
Pharmacology of corticosteroids
Pharmacology of corticosteroidsPharmacology of corticosteroids
Pharmacology of corticosteroids
Dalia Zaafar
 
Diabetes Overview
Diabetes OverviewDiabetes Overview
Diabetes Overview
MariaMohammad5
 
Insulin secretagogues
Insulin secretagoguesInsulin secretagogues
Insulin secretagogues
Bilal AL-mosheqh
 
Levocetirizine
LevocetirizineLevocetirizine
Levocetirizine
bdweiss
 
Glimepiride
GlimepirideGlimepiride
Empagliflozin
Empagliflozin Empagliflozin
Empagliflozin
MohammedMunirUddin2
 
Insulin sensitizers
Insulin sensitizersInsulin sensitizers
Insulin sensitizers
Viraj Shinde
 
Algorithms for Diabetes Management for Students
Algorithms for Diabetes Management for StudentsAlgorithms for Diabetes Management for Students
Algorithms for Diabetes Management for Students
Usama Ragab
 
Vildagliptin
Vildagliptin Vildagliptin
Vildagliptin
Sirinoot Jantharangkul
 
Recent advances in the management of Diabetes Mellitus
Recent advances in the management of Diabetes MellitusRecent advances in the management of Diabetes Mellitus
Recent advances in the management of Diabetes Mellitus
ShailaBanu3
 
Pharmacology (Corticosteroids Lecture)
Pharmacology (Corticosteroids Lecture)Pharmacology (Corticosteroids Lecture)
Pharmacology (Corticosteroids Lecture)
Ashfaq Ahmad
 
IDF DIABETES ATLAS
IDF DIABETES ATLASIDF DIABETES ATLAS
IDF DIABETES ATLAS
Centro Universitário Ages
 
Dpp4i earlier the better ! (1)
Dpp4i  earlier the better ! (1)Dpp4i  earlier the better ! (1)
Dpp4i earlier the better ! (1)
Faraz Farishta
 

What's hot (20)

Ryzodeg presentation in ramadan by dr shahjada selim
Ryzodeg presentation in ramadan by dr shahjada selimRyzodeg presentation in ramadan by dr shahjada selim
Ryzodeg presentation in ramadan by dr shahjada selim
 
Treatment of diabetes mellitus
Treatment of diabetes mellitusTreatment of diabetes mellitus
Treatment of diabetes mellitus
 
Pharmacotherapy of glaucoma
Pharmacotherapy of glaucomaPharmacotherapy of glaucoma
Pharmacotherapy of glaucoma
 
COPD new drugs new devices
COPD new drugs new devicesCOPD new drugs new devices
COPD new drugs new devices
 
sodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptx
sodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptxsodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptx
sodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptx
 
Voglibose
VogliboseVoglibose
Voglibose
 
Pharmacology of corticosteroids
Pharmacology of corticosteroidsPharmacology of corticosteroids
Pharmacology of corticosteroids
 
Diabetes Overview
Diabetes OverviewDiabetes Overview
Diabetes Overview
 
Insulin secretagogues
Insulin secretagoguesInsulin secretagogues
Insulin secretagogues
 
Levocetirizine
LevocetirizineLevocetirizine
Levocetirizine
 
Glimepiride
GlimepirideGlimepiride
Glimepiride
 
Empagliflozin
Empagliflozin Empagliflozin
Empagliflozin
 
Omalizumab
OmalizumabOmalizumab
Omalizumab
 
Insulin sensitizers
Insulin sensitizersInsulin sensitizers
Insulin sensitizers
 
Algorithms for Diabetes Management for Students
Algorithms for Diabetes Management for StudentsAlgorithms for Diabetes Management for Students
Algorithms for Diabetes Management for Students
 
Vildagliptin
Vildagliptin Vildagliptin
Vildagliptin
 
Recent advances in the management of Diabetes Mellitus
Recent advances in the management of Diabetes MellitusRecent advances in the management of Diabetes Mellitus
Recent advances in the management of Diabetes Mellitus
 
Pharmacology (Corticosteroids Lecture)
Pharmacology (Corticosteroids Lecture)Pharmacology (Corticosteroids Lecture)
Pharmacology (Corticosteroids Lecture)
 
IDF DIABETES ATLAS
IDF DIABETES ATLASIDF DIABETES ATLAS
IDF DIABETES ATLAS
 
Dpp4i earlier the better ! (1)
Dpp4i  earlier the better ! (1)Dpp4i  earlier the better ! (1)
Dpp4i earlier the better ! (1)
 

Similar to 12. antidiabetic drugs

BETH MARTINSExplain the difference  between the types of dia.docx
BETH MARTINSExplain the difference  between the types of dia.docxBETH MARTINSExplain the difference  between the types of dia.docx
BETH MARTINSExplain the difference  between the types of dia.docx
tangyechloe
 
Idf course module 1 introduction to diabetes
Idf course module 1 introduction to diabetesIdf course module 1 introduction to diabetes
Idf course module 1 introduction to diabetes
Diabetes for all
 
MANAGEMENTS ORTHODONTIC TREATMENT IN PATIENTS WITH DIABETES MELLITUS
MANAGEMENTS ORTHODONTIC TREATMENT IN PATIENTS WITH DIABETES MELLITUS MANAGEMENTS ORTHODONTIC TREATMENT IN PATIENTS WITH DIABETES MELLITUS
MANAGEMENTS ORTHODONTIC TREATMENT IN PATIENTS WITH DIABETES MELLITUS
Abu-Hussein Muhamad
 
Diabetes Mellitus Types Diet Maintenance and Exercise
Diabetes Mellitus Types  Diet Maintenance and ExerciseDiabetes Mellitus Types  Diet Maintenance and Exercise
Diabetes Mellitus Types Diet Maintenance and Exercise
shama shabbir
 
Diabetes notes by BISWANATH PRUSTY
Diabetes notes by BISWANATH PRUSTYDiabetes notes by BISWANATH PRUSTY
Diabetes notes by BISWANATH PRUSTY
College of pharmaceutical sciences
 
The Early Treatment of Type 2 Diabetes
The Early Treatment of Type 2 DiabetesThe Early Treatment of Type 2 Diabetes
The Early Treatment of Type 2 Diabetes
sanjelusbiswas1
 
Diabetis ppt
Diabetis pptDiabetis ppt
Diabetis ppt
Asraful Islam Rayhan
 
-2.pptx
-2.pptx-2.pptx
-2.pptx
DrVikasDubey2
 
DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUM
DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUMDIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUM
DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUM
Praveen Nagula
 
Diabetes and its Complication
Diabetes and its ComplicationDiabetes and its Complication
Diabetes and its Complication
Rajan Kumar
 
Peer #1 Nicholette ThomasTypes of diabetes          Type 1 .docx
Peer #1 Nicholette ThomasTypes of diabetes          Type 1 .docxPeer #1 Nicholette ThomasTypes of diabetes          Type 1 .docx
Peer #1 Nicholette ThomasTypes of diabetes          Type 1 .docx
pauline234567
 
36831.ppt
36831.ppt36831.ppt
36831.ppt
KhalidBassiouny1
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
DrManuSS
 
Application of epidemiology in Diabetic Mellitus NCD.pptx
Application of epidemiology in Diabetic Mellitus NCD.pptxApplication of epidemiology in Diabetic Mellitus NCD.pptx
Application of epidemiology in Diabetic Mellitus NCD.pptx
anjalatchi
 
36831
3683136831
Influence of systemic conditions on the periodontium
Influence of systemic conditions on the periodontiumInfluence of systemic conditions on the periodontium
Influence of systemic conditions on the periodontium
DR. OINAM MONICA DEVI
 
Diabetes at glance
Diabetes at glanceDiabetes at glance
Diabetes at glance
Rehab India Foundation
 

Similar to 12. antidiabetic drugs (20)

BETH MARTINSExplain the difference  between the types of dia.docx
BETH MARTINSExplain the difference  between the types of dia.docxBETH MARTINSExplain the difference  between the types of dia.docx
BETH MARTINSExplain the difference  between the types of dia.docx
 
Idf course module 1 introduction to diabetes
Idf course module 1 introduction to diabetesIdf course module 1 introduction to diabetes
Idf course module 1 introduction to diabetes
 
Med
MedMed
Med
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
MANAGEMENTS ORTHODONTIC TREATMENT IN PATIENTS WITH DIABETES MELLITUS
MANAGEMENTS ORTHODONTIC TREATMENT IN PATIENTS WITH DIABETES MELLITUS MANAGEMENTS ORTHODONTIC TREATMENT IN PATIENTS WITH DIABETES MELLITUS
MANAGEMENTS ORTHODONTIC TREATMENT IN PATIENTS WITH DIABETES MELLITUS
 
Diabetes Mellitus Types Diet Maintenance and Exercise
Diabetes Mellitus Types  Diet Maintenance and ExerciseDiabetes Mellitus Types  Diet Maintenance and Exercise
Diabetes Mellitus Types Diet Maintenance and Exercise
 
Diabetes notes by BISWANATH PRUSTY
Diabetes notes by BISWANATH PRUSTYDiabetes notes by BISWANATH PRUSTY
Diabetes notes by BISWANATH PRUSTY
 
The Early Treatment of Type 2 Diabetes
The Early Treatment of Type 2 DiabetesThe Early Treatment of Type 2 Diabetes
The Early Treatment of Type 2 Diabetes
 
Diabetis ppt
Diabetis pptDiabetis ppt
Diabetis ppt
 
-2.pptx
-2.pptx-2.pptx
-2.pptx
 
DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUM
DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUMDIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUM
DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUM
 
Diabetes and its Complication
Diabetes and its ComplicationDiabetes and its Complication
Diabetes and its Complication
 
Peer #1 Nicholette ThomasTypes of diabetes          Type 1 .docx
Peer #1 Nicholette ThomasTypes of diabetes          Type 1 .docxPeer #1 Nicholette ThomasTypes of diabetes          Type 1 .docx
Peer #1 Nicholette ThomasTypes of diabetes          Type 1 .docx
 
36831.ppt
36831.ppt36831.ppt
36831.ppt
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Application of epidemiology in Diabetic Mellitus NCD.pptx
Application of epidemiology in Diabetic Mellitus NCD.pptxApplication of epidemiology in Diabetic Mellitus NCD.pptx
Application of epidemiology in Diabetic Mellitus NCD.pptx
 
Dm 2
Dm 2Dm 2
Dm 2
 
36831
3683136831
36831
 
Influence of systemic conditions on the periodontium
Influence of systemic conditions on the periodontiumInfluence of systemic conditions on the periodontium
Influence of systemic conditions on the periodontium
 
Diabetes at glance
Diabetes at glanceDiabetes at glance
Diabetes at glance
 

More from DR.SAMINATHAN KAYAROHANAM

1. introduction of pharmacology
1. introduction of pharmacology1. introduction of pharmacology
1. introduction of pharmacology
DR.SAMINATHAN KAYAROHANAM
 
6. anticoagulants and antiplatelet agents
6. anticoagulants and antiplatelet agents6. anticoagulants and antiplatelet agents
6. anticoagulants and antiplatelet agents
DR.SAMINATHAN KAYAROHANAM
 
5. drugs for ischemic heart disease (ihd)
5. drugs for ischemic heart disease (ihd)5. drugs for ischemic heart disease (ihd)
5. drugs for ischemic heart disease (ihd)
DR.SAMINATHAN KAYAROHANAM
 
4. drug therapy for hypercholesterolemia
4. drug therapy for hypercholesterolemia4. drug therapy for hypercholesterolemia
4. drug therapy for hypercholesterolemia
DR.SAMINATHAN KAYAROHANAM
 
3. drug for arrhythmiasis
3. drug for arrhythmiasis3. drug for arrhythmiasis
3. drug for arrhythmiasis
DR.SAMINATHAN KAYAROHANAM
 
2. drugs for heart failure
2. drugs for heart failure2. drugs for heart failure
2. drugs for heart failure
DR.SAMINATHAN KAYAROHANAM
 
1. drugs for hypertension
1. drugs for hypertension1. drugs for hypertension
1. drugs for hypertension
DR.SAMINATHAN KAYAROHANAM
 
11. drugs affecting the endocrine system
11. drugs affecting the endocrine system11. drugs affecting the endocrine system
11. drugs affecting the endocrine system
DR.SAMINATHAN KAYAROHANAM
 
10. drugs for obesity
10. drugs for obesity10. drugs for obesity
10. drugs for obesity
DR.SAMINATHAN KAYAROHANAM
 
9. drug acting on the gastro intestinal system
9. drug acting on the gastro intestinal system9. drug acting on the gastro intestinal system
9. drug acting on the gastro intestinal system
DR.SAMINATHAN KAYAROHANAM
 

More from DR.SAMINATHAN KAYAROHANAM (10)

1. introduction of pharmacology
1. introduction of pharmacology1. introduction of pharmacology
1. introduction of pharmacology
 
6. anticoagulants and antiplatelet agents
6. anticoagulants and antiplatelet agents6. anticoagulants and antiplatelet agents
6. anticoagulants and antiplatelet agents
 
5. drugs for ischemic heart disease (ihd)
5. drugs for ischemic heart disease (ihd)5. drugs for ischemic heart disease (ihd)
5. drugs for ischemic heart disease (ihd)
 
4. drug therapy for hypercholesterolemia
4. drug therapy for hypercholesterolemia4. drug therapy for hypercholesterolemia
4. drug therapy for hypercholesterolemia
 
3. drug for arrhythmiasis
3. drug for arrhythmiasis3. drug for arrhythmiasis
3. drug for arrhythmiasis
 
2. drugs for heart failure
2. drugs for heart failure2. drugs for heart failure
2. drugs for heart failure
 
1. drugs for hypertension
1. drugs for hypertension1. drugs for hypertension
1. drugs for hypertension
 
11. drugs affecting the endocrine system
11. drugs affecting the endocrine system11. drugs affecting the endocrine system
11. drugs affecting the endocrine system
 
10. drugs for obesity
10. drugs for obesity10. drugs for obesity
10. drugs for obesity
 
9. drug acting on the gastro intestinal system
9. drug acting on the gastro intestinal system9. drug acting on the gastro intestinal system
9. drug acting on the gastro intestinal system
 

Recently uploaded

Pictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdfPictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdf
Dr. Rabia Inam Gandapore
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Top-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptxTop-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptx
SwisschemDerma
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
Lighthouse Retreat
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Effective-Soaps-for-Fungal-Skin-Infections.pptx
Effective-Soaps-for-Fungal-Skin-Infections.pptxEffective-Soaps-for-Fungal-Skin-Infections.pptx
Effective-Soaps-for-Fungal-Skin-Infections.pptx
SwisschemDerma
 
Colonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implicationsColonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implications
Dr Maria Tamanna
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
Sex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skullSex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skull
ShashankRoodkee
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
NEHA GUPTA
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
SwastikAyurveda
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 

Recently uploaded (20)

Pictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdfPictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdf
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Top-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptxTop-Vitamin-Supplement-Brands-in-India.pptx
Top-Vitamin-Supplement-Brands-in-India.pptx
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Effective-Soaps-for-Fungal-Skin-Infections.pptx
Effective-Soaps-for-Fungal-Skin-Infections.pptxEffective-Soaps-for-Fungal-Skin-Infections.pptx
Effective-Soaps-for-Fungal-Skin-Infections.pptx
 
Colonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implicationsColonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implications
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
Sex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skullSex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skull
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 

12. antidiabetic drugs

  • 1. BY Dr. SAMINATHAN KAYAROHANAM M.PHARM, PhD, M.B.A, PhD ANTIDIABETIC DRUGS 1
  • 2. 2 S.NO TITLE PAGE 1 OVERVIEW OF DIABETES MELLITUS 4-8 2 PATHOPHYSIOLOGY DIABETES MELLITUS 9 3 TYPES OF DIABETES 10 4 WHO DIABETES DIAGNOSTIC CRITERIA 18 5 MOST SIGNIFICANT SYMPTOMS OF DIABETES 19,20 6 CLASSIFICATION AND MECHANISM OF ANTIDIABETIC DRUG 21,22 7 CLASSIFICATION AND MECHANISAM OF INSULLIN 23-25 8 DURATION OF ACTION OF SOME ORAL HYPOGLYCEMIC AGENTS 26 9 SOME ADVERSE EFFECTS OBSERVED WITH ORAL HYPOGLYCEMIC AGENTS 27 10 ADVERSE EFFECTS OBSERVED WITH INSULIN 28 TABLE OF CONTENT Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D
  • 3. 3Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D LEARNING OUTCOMES 1. Able to understand the diabetes mellitus 2. Able to demonstrate the diagnosis and symptom of diabetes mellitus 3. Able to classified the different types of diabetes mellitus 4. Able to list the classification of drug used to treat diabetes mellitus 5. Able to demonstrate the various mechanism of anti-diabetes drugs 6. Able to understand some side effects of anti-diabetes drugs
  • 4. 4Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D  Diabetes mellitus is derived from the Greek word diabetes meaningsiphon - to pass through and the Latin word mellitus meaning honeyed or sweet. This is because in diabetes excess sugar is found in blood as well as the urine.  Diabetes mellitus (DM), commonly referred to as diabetes, is a group of metabolic diseases in which there are high blood sugar levels over a prolonged period. Symptoms of high blood sugar (hyperglycaemia) include frequent urination, increased thirst, and increased hunger.  Diabetes is a chronic disease, which occurs when the pancreas does not produce enough insulin, or when the body cannot effectively use the insulin it produces. This leads to an increased concentration of glucose in the blood  Type 1 diabetes (previously known as insulin-dependent or childhood-onset diabetes) is characterized by a lack of insulin production.  Type 2 diabetes (formerly called non-insulin-dependent or adult-onset diabetes) is caused by the body’s ineffective use of insulin. It often results from excess body weight and physical inactivity.  Gestational diabetes is hyperglycaemia that is first recognized during pregnancy. 1. OVERVIEW OF DIABETES MELLITUS
  • 5. 5Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D 1. About 347 million people worldwide have diabetes There is an emerging global epidemic of diabetes that can be traced back to rapid increases in overweight, including obesity and physical inactivity. 2. Diabetes is predicted to become the 7th leading cause of death in the world by the year 2030.Total deaths from diabetes are projected to rise by more than 50% in the next 10 years. 3. There are two major forms of diabetes Type 1 diabetes is characterized by a lack of insulin production and type 2 diabetes results from the body's ineffective use of insulin. 4. A third type of diabetes is gestational diabetes This type is characterized by hyperglycaemia, or raised blood sugar, with values above normal but below those diagnostic of diabetes, occurring during pregnancy. Women with gestational diabetes are at an increased risk of complications during pregnancy and at delivery. They are also at increased risk of type 2 diabetes in the future. 5. Type 2 diabetes is much more common than type 1 diabetes Type 2 accounts for around 90% of all diabetes worldwide. Reports of type 2 diabetes in children – previously rare – have increased worldwide. In some countries, it accounts for almost half of newly diagnosed cases in children and adolescents. WHO 10 FACTS OF DIABETES MELLITUS
  • 6. 6Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D 6. Cardiovascular disease is responsible for between 50% and 80% of deaths in people with diabetes Diabetes has become one of the major causes of premature illness and death in most countries, mainly through the increased risk of cardiovascular disease (CVD). 7. In 2012 diabetes was the direct cause of 1.5 million deaths. 8. 80% of diabetes deaths occur in low- and middle-income countries In developed countries most people with diabetes are above the age of retirement, whereas in developing countries those most frequently affected are aged between 35 and 64. 9. Diabetes is a leading cause of blindness, amputation and kidney failure Lack of awareness about diabetes, combined with insufficient access to health services and essential medicines, can lead to complications such as blindness, amputation and kidney failure. 10. Type 2 diabetes can be prevented Thirty minutes of moderate-intensity physical activity on most days and a healthy diet can drastically reduce the risk of developing type 2 diabetes. Type 1 diabetes cannot be prevented.
  • 8. 8Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D INTERNATIONAL DIABETES FEDERATION ESTIMATION IN 2015
  • 9. 9Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D 2. PATHOPHYSIOLOGY DIABETES MELLITUS
  • 10. 10Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D 3. TYPES OF DIABETES TYPE I (FORMALLY IDDM OR JUVENILE) TYPE II (FORMALLY NIDDM OR ADULT) SECONDARY DIABETES (OCCUR ONLY IF THERE IS AN UNDERLYING DISEASE) E,G,: CUSHING DISEASE, PANCREATECTOMY, GROWTH HORMONE TUMOR. GESTATIONAL DIABETES
  • 11. 11Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D TYPE 1 DIABETES A chronic condition in which the pancreas produces little or no insulin.
  • 12. 12Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D TYPE 2 DIABETES A chronic condition that affects the way the body processes blood sugar (glucose).
  • 13. 13Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D A form of high blood sugar affecting pregnant women. GESTATIONAL DIABETES
  • 14. 14Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D DIFFERENT BETWEEN TYPE1 AND 2
  • 15. 15Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D DIFFERENT BETWEEN TYPE1 AND 2
  • 16. 16Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D DIFFERENT BETWEEN TYPE1 AND 2
  • 17. 17Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D COMPARISON OF TYPE 1 AND 2 DIABETES
  • 18. 18Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D 4. WHO DIABETES DIAGNOSTIC CRITERIA •Fasting plasma glucose level ≥ 7.0 mmol/l (126 mg/dl) •Plasma glucose ≥ 11.1 mmol/l (200 mg/dl) two hours after a 75 g oral glucose load as in a glucose tolerance test •Symptoms of high blood sugar and casual plasma glucose ≥ 11.1 mmol/l (200 mg/dl) •Glycated hemoglobin (HbA1C) ≥ 48 mmol/mol (≥ 6.5 DCCT %)
  • 19. Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D 19 5. MOST SIGNIFICANT SYMPTOMS OF DIABETES
  • 20. 20Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D MOST SIGNIFICANT SYMPTOMS OF DIABETES
  • 21. 21Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D 6.CLASSIFICATION AND MECHANISM OF ANTIDIABETIC DRUG 1 3 2
  • 22. 22Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D SUMMARY OF ORAL AGENTS USED TO TREAT DIABETES 4 7 6 5
  • 23. 23Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D 7.CLASSIFICATION AND MECHANISAM OF INSULLIN
  • 24. Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D 24 7. MECHANISAM OF INSULLIN
  • 25. 25Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D INJECTION LOCATION OF INSULLIN
  • 26. 26Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D 8. DURATION OF ACTION OF SOME ORAL HYPOGLYCEMIC AGENTS
  • 27. 27Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D 9. SOME ADVERSE EFFECTS OBSERVED WITH ORAL HYPOGLYCEMIC AGENTS
  • 28. 28Dr.K.Saminathan.M.Pharm, PhD, M.B.A, Ph.D 10. ADVERSE EFFECTS OBSERVED WITH INSULIN